On the basis of our results, we agree with previous studies in human and veterinary medicine that have shown that claudin-1 in combination with other antibodies could serve as a useful marker to distinguish NSTs from other spindle cell tumors and, moreover, to subclassify NSTs [25,38,51]. The gene discussed is CLDN1; the disease is spindle cell neoplasm.